Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis

Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis

AbstractBackground There is a lack of evidence regarding whether combination therapy of hypomethylating agents (HMAs) has better outcomes than HMA monotherapy in patients with Philadelphia chromosome-negative accelerated or blast phase myeloproliferative neoplasms (MPN-AP/BP).Materials and methods P...

Full description

Bibliographic Details
Main Authors: Jia Chen, Kefei Wang, Zhijian Xiao, Zefeng Xu
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Annals of Medicine
Subjects:
Myeloproliferative neoplasms
accelerated/blast phase
hypomethylating agents
ruxolitinib
venetoclax
Online Access:https://www.tandfonline.com/doi/10.1080/07853890.2022.2164611

Internet

https://www.tandfonline.com/doi/10.1080/07853890.2022.2164611

Similar Items